BioVie Inc (NASDAQ:BIVI) shares are trading higher after the drug developer announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024.
The Carson City, Nevada-based company’s stock is trading on a session volume of 8.96 million compared to an average volume of 536.8K, as per data from Benzinga Pro.
Improvements in non-motor symptoms correlated with improvements in motor symptoms for Parkinson’s Disease patients.
- Data from phase 2a placebo-controlled study suggest improvements in NE3107-treated patients with non-motor symptoms.
- NE3107-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159).
- Sleep/fatigue domain improvements correlated with motor score improvements.
- More ...